Explore this research category across breast cancer datasets
| RNA Name | Mechanism of Action | Effect on Cancer | Cancer Type | Reference |
|---|---|---|---|---|
|
FDX1
mRNA |
FDX1 (ferredoxin 1) is a core cuproptosis regulator that promotes protein lipoylation and sensitizes cells to copper-induced DLAT oligomerization and proteotoxic stress. | In TNBC models, FDX1 activity/state is linked to cuproptosis sensitivity and tumor growth: AKT1 phosphorylation of FDX1 was reported to mediate cuproptosis resistance in TNBC, and FDX1 knockdown reduced tumor growth and affected CD8?? T-cell responses. | Breast Cancer |
PubMed
Reference PMID: 40911146 |
|
DLAT
mRNA |
lipoylated and, upon copper binding/oligomerization, undergoes toxic aggregation that is central to cuproptosis execution. | targeting DLAT-dependent processes sensitizes TNBC cells to copper ionophores. | Breast Cancer |
PubMed
Reference PMID: 39460738 |
|
LIPT1
mRNA |
Required for protein lipoylation and the DLAT-dependent proteotoxic aggregation that defines cuproptosis. | Multiple bioinformatic and review papers report differential expression or prognostic associations of these genes in breast cancer / TNBC and propose that their expression/state determines cuproptosis susceptibility; experimental TNBC validation is emerging. | Breast Cancer |
PubMed
Reference PMID: 37853210 |
|
DLD
mRNA |
Required for protein lipoylation and the DLAT-dependent proteotoxic aggregation that defines cuproptosis. | Multiple bioinformatic and review papers report differential expression or prognostic associations of these genes in breast cancer / TNBC and propose that their expression/state determines cuproptosis susceptibility; experimental TNBC validation is emerging. | Breast Cancer |
PubMed
Reference PMID: 37853210 |
|
PDHA1
mRNA |
Required for protein lipoylation and the DLAT-dependent proteotoxic aggregation that defines cuproptosis. | Multiple bioinformatic and review papers report differential expression or prognostic associations of these genes in breast cancer / TNBC and propose that their expression/state determines cuproptosis susceptibility; experimental TNBC validation is emerging. | Breast Cancer |
PubMed
Reference PMID: 37853210 |
|
ATP7B
mRNA |
Copper efflux pump ATP7B modulates cellular copper homeostasis and can decrease cuproptosis susceptibility. | Reported in pan-cancer/cuproptosis signatures and may contribute to therapy resistance via copper handling in breast tumors. | Breast Cancer |
PubMed
Reference PMID: 37853210 |
|
SLC31A1
mRNA |
Copper importer (CTR1) increases cellular copper uptake, promoting susceptibility to cuproptosis when mitochondrial lipoylated proteins are overloaded. | Upregulated in breast cancer and associated with worse prognosis; part of proposed LINC01640/miR-204-5p?SLC31A1 cuproptosis axis. | Breast Cancer |
PubMed
Reference PMID: 37884650 |
|
TFRC
mRNA |
Transferrin receptor?1 imports iron and increases labile Fe2+, sensitizing to ferroptosis. | ER?negative/TNBC cells with higher TFRC show greater sensitivity to sulfasalazine?induced ferroptosis. | Breast Cancer |
PubMed
Reference PMID: 31173262 |
|
IFNG
mRNA |
IFN??/JAK?STAT�IRF1 axis transcriptionally activates ALOX15B, enhancing lipid peroxidation and ferroptosis sensitivity in TNBC cells. | Sensitizes TNBC cells to ferroptosis; tumor?suppressive. | Breast Cancer |
PubMed
Reference PMID: 33495298 |
|
GSK3B
mRNA |
Positive modulator of ferroptosis; active GSK3? disrupts iron homeostasis (affects DMT1/FTH1/FTL) to increase labile iron and ferroptosis sensitivity. | In PTEN?KO MDA?MB?231 (TNBC) cells, increased pGSK3?Ser9 (inactive) associates with higher NRF2/xCT and resistance to ferroptosis; implies active GSK3? enhances sensitivity. | Breast Cancer |
PubMed
Reference PMID: 34732689 |